A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
In the 2000s, when the AIDS pandemic hit South Africa, we were seeing a lot of children dying from HIV. That was just before ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.
Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...
The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...
SAQE, a tool with over 90% accuracy for diagnosing Hypersensitivity Pneumonitis. This lung condition, prevalent in South Asia, leads to fibrosis. The tool uses a questionnaire to assess environmental ...
Almost half of patients with recurrent/metastatic disease responded to trastuzumab pamirte ...
A new study suggests that COVID-19 may slightly increase the risk of lung cancer by triggering a biological chain reaction in ...
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.